Investigations of short-chain fatty acids in humans

Clinical Nutrition, Supplement

Volumn 1, Issue 2, 2004, Pages 19-23

  Rombeau, John L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Butyrate; Short chain fatty acids

Indexed keywords

BUTYRIC ACID; CARBOHYDRATE; ENEMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT CHAIN FATTY ACID;

CLINICAL TRIAL; COLON ABSORPTION; COLON DISEASE; DIETARY FIBER; HUMAN; LOWER ESOPHAGUS SPHINCTER; PROCTITIS; PROCTOSIGMOIDITIS; REVIEW; ULCERATIVE COLITIS;

EID: 23744467969     PISSN: 17441161     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2004.09.004     Document Type: Article

References (11)

1. Musch MW, Bookstein C, Xie Y, et al. SCFA increase intestinal Na absorption by induction of NHE3 in rat colon and human intestinal C2/bbe cells. Am J Physiol Gastrointest Liver Physiol 2001;280:G687-93.
2. Piche T, Zerbib F, Des Varrannes SB, et al. Modulation by colonic fermentation of LES function in humans. Am J Physiol Gastrointest Liver Physiol 2000;278:0578-84.
3. Inan MS, Rasoulpour RJ, Yin L, et al. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gostroenterology 2000;118: 724-34.
4. Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomized, crossover trial. Lancet 2000;356:1232-335.
5. Otchy DP, Nelson H. Radiation injuries of the colon and rectum. Surg Clin North Am 1993;73:1017-35.
6. Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis. Dis Colon Rectum 1999;42:788-95.
7. Lührs H, Gerke E, Müller G, et al. Butyrate inhibits NF-κB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002;4: 458-66.
8. DeMichele SJ, Karlstad MD. Short-chain triglycerides in clinical nutrition. In: Cummings JH, Rombeau JL, Sakata T, editors. Physiologic and clinical aspects of short chain fatty acids. Cambridge: Cambridge University Press; 1995. p. 537-59.
9. Newmark HL, Lupton JR, Young CW. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett 1994;78:1-5.
10. Conley BA, Egorin MJ, Tait N, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998;4:629-34.
11. Hallert C, Björck I, Nyman M, et al. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflammatory Bowel Dis 2003;9:116-21.